MARKET WIREReuters • 2h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why BON Stock Traded Steady Today — RQD Quant Desk Flash
$1.13 -0.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.13
Bon Natural Life Limited (Class A) (BON) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $9.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BON Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Bon Natural Life Limited (Class A) (NASDAQ: BON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.13 (-0.01% 1D, market cap $9.2M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BON ranks #490 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BON compare to NAII and MTEX in the Health Care sector?
▼
Within the Health Care sector (Medicinal Chemicals and Botanical Products), BON carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 20.8%, and ROIC of —. By comparison, NAII (Natural Alternatives International Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -10.8%, cap $6.9M) and MTEX (Mannatech Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, BON leads on earnings multiple (N/A) while BTMD leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BON?
▼
Per BON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001816815), Bon Natural Life Limited (Class A) generated $18.7M in revenue (-21.7% YoY), -$2.0M in net income, and $134.3K in free cash flow against $85.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (21% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.13 (-0.19%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 0.7% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-6.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BON)Realized 20D OHLCV Swing Band: ±9.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY BON SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (36% of score)
SEC XBRL FY 2025 (10-K): 0.7% FCF Margin ($134.3K FCF) & 20.8% Gross Margin
▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (18% of score)
20D Institutional Volume Accumulation (±9.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$1.16-1.7% Next Q
53
Q2 (-2Q)Grade C-$1.14+0.9% Next Q
50
Q3 (-1Q)Grade D$1.15-1.7% Next Q
48
CurrentGrade D$1.13-6.3% Hist 90D α
45
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BON Turnaround Squeeze
While BON currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Strong cash generator (21% profit margin)—profits are backed by real money, not accounting tricks.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($1.19) forces dealer call-delta covering toward $2.16.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BON• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BON Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BON Stock Traded Steady Today — RQD Quant Desk Flash
Bon Natural Life Limited (Class A) (BON) slipped -0.01% to $1.13, trading at 16% of its 52-week range ($0.95 – $2.06). Stretched risk/reward at current multiples (21% profit margin) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($0.95 – $2.06) with RSI-14 at 48 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.5% around $1.13 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 20.8% gross margin and $134288 annual free cash flow.
Live BON Headlines & Catalysts
MARKET WIREReuters • 2h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 4h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 5h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 7h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 8h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 9h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 11h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BON)
- ✓Walkthrough of BON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.72%📐 HORIZONTAL RANGE
2026-10-30O $1.15H $1.15L $1.10C $1.13VOL 23.2K
RES: $1.27SUP: $0.90SMA50: $1.15SMA200: $1.30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -21.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BON today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BON. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BON)
Health Care Rank #490 of 1016
⚔️ NAII vs BON Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BON vs. NAII, MTEX, AKAN, BTMD)
Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Bon Natural Life Limited (Class A) (BON) ranks #490 by composite RQD confidence (45/100, grade D) and #901 by equity capitalization ($9.2M). Within this direct 5-issuer industry benchmark cohort, BON leads on earnings valuation at N/A trailing P/E, while BTMD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with BON at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BON
ACTIVE
Bon Natural Life Limited (Class A) | D | 45/100 | — | 20.8% | — | -0.01% | $9.2M | Benchmark Subject |
| NAII Natural Alternatives International Inc. | E | 34/100 | — | 7.2% | -10.8% | -4.31% | $6.9M | /naii-vs-bon → |
| MTEX Mannatech Incorporated | E | 33/100 | — | 74.9% | -35.0% | -2.23% | $16.1M | /mtex-vs-bon → |
| AKAN Akanda Corp. | D+ | 54/100 | — | — | — | +2.80% | $2.6M | /akan-vs-bon → |
| BTMD Biote Corp. (Class A) | C | 62/100 | — | — | 85.0% | +1.74% | $42.0M | /btmd-vs-bon → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001816815In its most recent audited fiscal period (FY2025, filed 2025-09-30), Bon Natural Life Limited (Class A) (BON) reported GAAP revenue of $18.7M (-21.7% vs. FY2024 revenue of $23.8M , and -36.8% cumulative change since FY2023) , GAAP net income of -$2.0M, operating cash flow of $141.1K, and free cash flow of $134.3K (+101.7% YoY). On the balance sheet, BON closed FY2025 with $85.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $18.7M | -$2.0M | $141.1K | $134.3K | $85.2M | — |
| FY2024 (FY) | 2024-09-30 | $23.8M | $398.2K | -$7.7M | -$7.7M | — | — |
| FY2023 (FY) | 2023-09-30 | $29.5M | $4.6M | -$616.9K | -$616.9K | — | — |
3. BON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Bon Natural Life Limited (Class A) (NASDAQ: BON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.13 (-0.01% 1D, market cap $9.2M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BON ranks #490 in composite RQD confidence.
How does BON compare to NAII and MTEX in the Health Care sector?
Within the Health Care sector (Medicinal Chemicals and Botanical Products), BON carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 20.8%, and ROIC of —. By comparison, NAII (Natural Alternatives International Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -10.8%, cap $6.9M) and MTEX (Mannatech Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, BON leads on earnings multiple (N/A) while BTMD leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BON?
Per BON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001816815), Bon Natural Life Limited (Class A) generated $18.7M in revenue (-21.7% YoY), -$2.0M in net income, and $134.3K in free cash flow against $85.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (21% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BON trading relative to its 50-day, 200-day, and 52-week technical levels?
BON last traded at $1.13 (-0.01% on volume of 1,385 shares), positioning the stock -1.74% below its 50-day simple moving average ($1.15) and -13.08% below its 200-day simple moving average ($1.30). Across its 52-week range of $0.95 to $2.06, BON sits at the 16.2% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($1.02 to $1.24).
BON Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BON stock moving today?
Why BON Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (21% profit margin) under elevated 10-year interest-rate pressure.